Evidence map›Paper›PMID 25963029›Full record

ArticleChinese journal of cancer2015

Cancer research in the era of next-generation sequencing and big data calls for intelligent modeling.

Jari Yli-Hietanen, Antti Ylipää, Olli Yli-Harja

Abstract readEditorial
In one paragraph

Article in Chinese journal of cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Deep Sequencing of Urinary RNAs for Bladder Cancer Molecular Diagnostics.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jari Yli-HietanenDepartment of Signal Processing, Tampere University of Technology, P. O. Box 553, Tampere, 33101, Finland. jari.yli-hietanen@tut.fi.
Antti YlipääDepartment of Signal Processing, Tampere University of Technology, P. O. Box 553, Tampere, 33101, Finland. antti.ylipaa@tut.fi.
Olli Yli-HarjaDepartment of Signal Processing, Tampere University of Technology, P. O. Box 553, Tampere, 33101, Finland. yliharja@cs.tut.fi.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We examine the role of big data and machine learning in cancer research. We describe an example in cancer research where gene-level data from The Cancer Genome Atlas (TCGA) consortium is interpreted using a pathway-level model. As the complexity of computational models increases, their sample requirements grow exponentially. This growth stems from the fact that the number of combinations of variables grows exponentially as the number of variables increases. Thus, a large sample size is needed. The number of variables in a computational model can be reduced by incorporating biological knowledge. One particularly successful way of doing this is by using available gene regulatory, signaling, metabolic, or context-specific pathway information. We conclude that the incorporation of existing biological knowledge is essential for the progress in using big data for cancer research.

Indexed as

Computer SimulationHigh-Throughput Nucleotide SequencingNeoplasmsGenomeHumans

Identifiers

PMID25963029
PMCPMC4593335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.